Misetionamide (GP-2250) in combination with gemcitabine has demonstrated a good safety profile and potential therapeutic benefit in the treatment of pancreatic adenocarcinoma.

Panavance Therapeutics revealed the interim data from its Phase I clinical study at the 2024 Visceral Medicine Congress in Leipzig, Germany.

The Phase I dose escalation clinical trial is enrolling patients with advanced unresectable or metastatic pancreatic ductal adenocarcinoma (PDAC) as a second line therapy for patients who have previously received a first line 5FU containing regimen (e.g. FOLFIRINOX/NALIRIFOX).

This interim data presented includes 49 patients across 11 cohorts. The safety profile to date has shown zero grade ≥3 adverse events in an initial monotherapy treatment.

During the combination therapy with gemcitabine, a total of five grade 3 events, and a total of 10 grade 4 events have been observed with all definitely attributed to gemcitabine, and one possibly attributed to misetionamide.

The progression free survival of patients treated with the misetionamide-gemcitabine combination compares favourably to historical comparison to gemcitabine alone.

There have been six partial responders (>30% tumour reduction) thus far including one partial response patient who remained on study 24 months.

Anup Kasi, Associate Professor, Medical Oncology, University of Kansas Cancer Center and primary investigator for the ongoing Phase I clinical trial, said: “Data from this interim update of the ongoing trial, including initial efficacy together with a very acceptable safety and tolerability profile, support the promise of the misetionamide-gemcitabine combination as a potential new option for the treatment of pancreatic cancer patients.”

Misetionamide’s unique mechanism of action

Misetionamide is a broadly active small molecule with a unique mechanism of action that inhibits two oncogenic transcription factors, c-MYC and NFκB. Acting through c-MYC, misetionamide selectively disrupts the energy metabolism of cancer cells leading to cancer cell death.

Through NFκB inhibition, misetionamide inhibits cancer cells’ ability to proliferate and survive. This mechanism makes misetionamide an attractive tumour cell selective agent.

The company plans to initiate a clinical trial of misetionamide for the treatment of platinum-resistant ovarian cancer and a clinical trial as a first-line maintenance therapy for non-BRCA mutated pancreatic cancer patients.

Preclinical studies have demonstrated that misetionamide has the potential to be effective in additional tumour types, including melanoma, squamous cell, breast, and colorectal cancers.

“We are pleased to share, for the first time, an interim look at the data from our ongoing Phase I dose escalation study. The trial is now at cohorts where the dose levels are in the range (on a mg/kg basis) where effectiveness was observed in the preclinical models. We continue to focus on completing the Phase I study with four US clinical trial sites and look forward to providing further clinical data updates in 2025,” said Greg Bosch, Panavance Chairman and CEO.

Diana Spencer, Senior Digital Content Editor, DDW